AlphAIAlphAI — Financial news for AI agents
simplywall.stSEP 123 min read$JNJ

Johnson & Johnson (JNJ) Weighs DePuy Synthes Exit In MedTech Portfolio Reset

Johnson & Johnson (JNJ) is considering selling its DePuy Synthes orthopedics unit to Apollo Global Management. This potential sale is part of a broader restructuring of J&J's MedTech portfolio. The company has a market value of approximately $641.9 billion. The sale could focus J&J's device mix and improve MedTech margins, according to analysts.

Original reporting
simplywall.st
Published Sep 12, 2026, 10:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 13, 2026, 7:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$JNJ
Neutral
high confidence
Mentioned
$JNJ
Relevance
7/10
AlphAI data visualization · based on simplywall.st
Decision brief

The 30-second read

$JNJNeutralMed
01

Why it matters

Divesting DePuy Synthes may free capital and sharpen focus on higher‑margin MedTech opportunities, potentially boosting long‑term earnings.

02

Market read

The potential transaction is material for JNJ shareholders and could influence broader MedTech valuations.

03

What to watch

Regulatory approval risk and integration challenges for Apollo may temper upside.

Relevance 7/10Novelty 7/10Timing: as of publication

Background

Johnson & Johnson's diversified health business includes pharmaceuticals, medical devices, and consumer health. The DePuy Synthes unit is a key orthopedics platform.

Company-level read

Ticker impact

$JNJNeutralHigh confidence
Context

Johnson & Johnson is reported to be in talks to sell its DePuy Synthes orthopedics unit to Apollo Global Management.

Expected impact

Possible short-term downside pressure on JNJ as investors price in the sale uncertainty.

Evidence & confidence

The news is a first‑report of a major M&A discussion involving a large business segment of a mega‑cap company.

Market effects

Sector

MedTech sector may see consolidation pressure as J&J trims its orthopedics exposure.

Regional

U.S. healthcare stocks could react to the potential shift in J&J's portfolio focus.

Global

Large‑cap healthcare investors worldwide will monitor the deal for valuation impact.

Counterpoint

What could challenge this read

The sale could be a catalyst for a rebound if proceeds are redeployed into higher‑growth areas.

Key entities

  • Company
    Johnson & Johnson

    U.S. healthcare conglomerate considering sale of its orthopedics unit.

  • Private Equity
    Apollo Global Management

    Potential buyer of DePuy Synthes.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 15
$JNJMedAI 9/10

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026

Johnson & Johnson (JNJ) presented Phase 2b COPERNICUS study results at WCLC 2026, showing low rates of treatment-related events for RYBREVANT FASPRO (amivantamab) plus LAZCLUZE (lazertinib) in advanced NSCLC. Fewer than 1% of patients discontinued treatment at one year. The study supports the regimen's safety and tolerability, building on prior survival benefits.

prnewswire.com2 min
SEP 14
$JNJHighAI 9/10

JNJ Looks 37.8% Overvalued on GF Value™ as Dividend Sustainabili

Johnson & Johnson (JNJ) announced that its experimental treatment JNJ-5120/PIPE-307 failed to meet the primary endpoint in a phase 2 trial for major depressive disorder. The company's dividend yield is 1.95% with a payout ratio of 50% and a 3-year growth rate of 4.9%. JNJ's stock is trading 37.8% above its intrinsic GF Value™ of $193.33, with a GF Score™ of 83/100. Insiders have sold $154.9 million in shares over the past year.

gurufocus.com3 min
SEP 14
$JNJHighAI 9/10

J&J explores $20B DePuy Synthes sale to Apollo

Johnson & Johnson (JNJ) is in talks to sell its DePuy Synthes orthopedics unit to Apollo Global Management for $20B. DePuy Synthes generated $9.3B in sales last year. The deal, if finalized, would be Apollo's largest healthcare investment. JNJ is also considering other separation options, including a spin-off, to maximize shareholder value.

grafa.com2 min
SEP 14
$JNJHighAI 9/10

J&J in talks to sell DePuy Synthes to Apollo for $20 billion

Johnson & Johnson (JNJ) is in talks to sell its orthopedics unit, DePuy Synthes, to Apollo Global Management for approximately $20 billion. The unit generated $9.3 billion in sales last year. J&J may also consider spinning off the business as a standalone company. J&J's second-quarter sales were $25.31 billion, with the MedTech unit, including DePuy Synthes, recording $8.93 billion in sales.

yahoo.com2 min
SEP 14
$JNJHighAI 9/10

Amivantamab regimen delivers longest survival in EGFR Ex20ins lung cancer

Johnson & Johnson reported final results from the PAPILLON study, showing its amivantamab-based regimen achieved a median overall survival of 34.3 months in EGFR Ex20ins lung cancer patients, compared to 27.9 months for chemotherapy alone. The findings were presented at the IASLC 2026 World Conference on Lung Cancer. According to the company, the regimen demonstrated durability and value as a first-line treatment. The safety profile was consistent with earlier studies.

pharmatimes.com2 min